New NIH grant to advance joint UMCP and UMB brain surgery robot development

A research team from the University of Maryland, College Park (UMCP) and the University of Maryland, Baltimore (UMB) have been awarded a new $2 million grant from the National Institutes of Health (NIH) to continue developing a small robot that could one day be a huge aid to neurosurgeons in removing difficult-to-reach brain tumors. This NIH grant is one of the first awarded to a joint UMB and UMCP research project under the collaboration between these two research powerhouses that is known as University of Maryland: MPowering the State.

Team members Jaydev P. Desai, PhD, associate professor of mechanical engineering at UMCP, and Rao Gullapalli, MD, associate professor of diagnostic radiology and nuclear medicine, and J. Marc Simard, MD, professor of neurosurgery, both at the University of Maryland School of Medicine in Baltimore have developed their "Minimally Invasive Neurosurgical Intracranial Robot" (MINIR) prototype over a number of years and demonstrated its feasibility, supported in part by a previous NIH grant. The team has evaluated the device under continuous magnetic resonance imaging (MRI). According to the researchers, work done on the previous NIH grant helped to uncover next level challenges that are the basis of this new NIH project.

The NIH grant will enable the team to develop MINIR-II, a fully MRI-compatible robot and demonstrate its safety and effectiveness. To accomplish this, MINIR-II will need to be under the direct control of the physician, with targeting information obtained exclusively from real-time MRI that uses active targeting methods with sensors embedded within MINIR-II.

"This technology has the potential to revolutionize the treatment and management of patients with difficult to reach intracranial tumors and to have a direct impact on improving their quality of life," says Dr. Desai. "This work is a result of exceptional collaboration over the years, between our two extraordinary institutions."

Brain tumors are among the most feared complications of cancer, occurring in 20 to 40 percent of adult cancer patients. Despite numerous advances in treatment, the prognosis for these patients is poor, with a median survival of 4